Saturday 17 October 2026
Export ETON’s income statement to Excel — free account
Eton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024. In the quarter to June 2026, revenue grew 98.6%, EPS grew 520.0%, free cash flow fell 8.78% and total debt fell 7.54%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
50.40
0.93
−1.81%
Follow ETON
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 77.02 |
P/S ratio |
8.31 | 5.69 | 7.75 | 9.48 | |
P/FCF ratio |
45.32 | 220.99 | 0.00 | 0.00 | |
P/Operating CF |
48.59 | (39.39) | 90.94 | 137.92 | |
P/B ratio |
25.27 | 17.40 | 22.00 | 21.48 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 1,103.24 | |
EV/Sales |
8.21 | 5.75 | 7.87 | 9.49 | |
EV/EBITDA |
255.25 | 117.97 | 101.83 | 46.63 | |
EV/Operating CF |
27.11 | 43.67 | 43.21 | 66.18 | |
EV/FCF |
44.80 | 223.23 | (88.88) | (119.42) | |
Quick Ratio |
1.14 | 0.98 | 0.75 | 1.15 | |
Current Ratio |
1.63 | 1.57 | 1.21 | 1.52 | |
Net Debt/EBITDA |
38.59 | 1.26 | 3.03 | 0.07 | |
Debt/Assets |
29.06% | 33.17% | 31.47% | 24.09% | |
Debt/Equity |
1.31 | 1.17 | 1.00 | 0.60 | |
Asset Turnover |
1.00 | 0.95 | 0.96 | 0.97 | |
Operating CF/Net income |
(6.24) | (7.79) | 4.77 | 0.63 | |
Capex/Depreciation |
(0.24) | (0.04) | (12.07) | 0.00 | |
Interest Coverage |
(2.30) | — | 2.87 | 11.89 | |
Research and Development Expense of Revenue |
4.95% | 8.36% | 7.73% | 2.64% | |
Selling, General and Administrative Expense of Revenue |
36.09% | 41.61% | 43.05% | 30.93% | |
Intangible Assets out of Total Assets |
0.31 | 0.34 | 0.45 | 0.39 | |
Share Based Compensation of Revenue |
4.86% | 5.28% | 6.26% | 3.91% | |
Graham Net Nets |
(0.02) | (0.01) | (0.02) | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 4.22 | |
Earnings Yield |
(1.15%) | (1.01%) | (0.20%) | 1.30% | |
Free Cash Flow Yield |
2.21% | 0.45% | (1.14%) | (0.84%) | |
Revenue per Share |
0.84 | 0.79 | 0.89 | 1.36 | |
Operating CF per Share |
0.45 | (0.43) | 0.27 | 0.26 | |
Capex per Share |
(0.01) | 0.00 | (0.55) | 0.00 | |
Free Cash Flow per Share |
0.44 | (0.43) | (0.28) | 0.26 | |
Cash per Share |
1.38 | 0.96 | 0.72 | 0.97 | |
Shareholders Equity per Share |
0.86 | 0.97 | 1.12 | 1.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.86 | 0.97 | 1.12 | 1.69 | |
Free Cash Flow |
11.74 | (11.60) | (7.67) | 7.26 | |
Working Capital |
27.82 | 22.09 | 9.07 | 23.48 | |
Capital Expenditures |
(0.28) | (0.05) | (15.07) | 0.01 | |
Net Current Asset Value |
(9.38) | (5.38) | (13.85) | (0.62) | |
EV/EBIT |
0.00 | 0.00 | 335.53 | 61.42 | |
Capex to Sales |
0.01 | 0.00 | 0.62 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 330.10 | 61.36 | |
| Other line items | |||||
Average Receivables |
9.34 | 8.56 | 14.90 | 19.67 | |
Average Payables |
8.47 | 7.57 | 9.18 | 13.27 | |
Average Inventory |
9.40 | 15.33 | 14.04 | 16.97 | |
Average Assets |
70.18 | 84.12 | 90.87 | 108.74 | |
Average Common Equity |
19.55 | 25.29 | 27.53 | 35.27 |
Columns are period end dates